Ethnic differences in the distribution of CYP3A5 gene polymorphisms

References

• Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G, Buchler M, Laurent-Puig P, Tregouet D, Beaune P, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clinical Pharmacology and Therapy 2004; 75: 422–433
   PubMed Web of Science ®Google Scholar
• Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV, et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. Journal of Biology and Chemistry 1989; 264: 10388–10395
   PubMed Web of Science ®Google Scholar
• Cauffiez C, Pottier N, Tournel G, Lo-Guidice JM, Allorge D, Chevalier D, Migot-Nabias F, Kenani A, Broly F. CYP2A13 genetic polymorphism in French Caucasian, Gabonese and Tunisian populations. Xenobiotica 2005; 35: 661–669
   PubMed Web of Science ®Google Scholar
• Chevalier D, Allorge D, Lo-Guidice JM, Cauffiez C, Lepetit C, Migot-Nabias F, Kenani A, Lhermitte M, Broly F. Sequence analysis, frequency and ethnic distribution of VNTR polymorphism in the 5′-untranslated region of the human prostacyclin synthase gene (CYP8A1). Prostaglandins and Other Lipid Mediators 2002; 70: 31–37
   PubMed Web of Science ®Google Scholar
• Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends in Pharmacology Science 1992; 13: 434–439
   PubMed Web of Science ®Google Scholar
• Chou FC, Tzeng SJ, Huang JD. Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metabolism and Disposition 2001; 29: 1205–1209
   PubMed Web of Science ®Google Scholar
• Chowbay B, Zhou S, Lee EJ. An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: Experience in Singapore. Drug Metabolism Review 2005; 37: 327–378
   PubMed Web of Science ®Google Scholar
• Daly AK. Significance of the minor cytochrome P450 A isoforms. Clinical Pharmacokinetics 2006; 45: 13–31
   PubMed Web of Science ®Google Scholar
• Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annual Review of Medicine 2006; 57: 119–137
   PubMed Web of Science ®Google Scholar
• Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, et al. Swiss HIV Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet 2002; 359: 30–36
   PubMed Web of Science ®Google Scholar
• Givens RC, Lin YS, Dowling AL, Thummel KE, Lamba JK, Schuetz EG, Stewart PW, Watkins PB. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. Journal of Applied Physiology 2003; 95: 1297–1300
   PubMed Web of Science ®Google Scholar
• Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147–154
   PubMedGoogle Scholar
• Hesselink DA, Van Schaik RH, Van der Heiden IP, Van der Werf M, Gregoor PJ, Lindemans J, Weimar W, Van Gelder T. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clinical Pharmacology and Therapy 2003; 74: 245–254
   PubMed Web of Science ®Google Scholar
• Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773–779
   PubMedGoogle Scholar
• Jounaidi Y, Hyrailles V, Gervot L, Maurel P. Detection of CYP3A5 allelic variant: A candidate for the polymorphic expression of the protein?. Biochemistry and Biophysics Research Communications 1996; 221: 466–470
   PubMed Web of Science ®Google Scholar
• Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, Orza D, Marinina J, Gerber N. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metabolism and Disposition 1998; 26: 552–561
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics 2001; 27: 383–391
   PubMed Web of Science ®Google Scholar
• Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E, Mohrenweiser HW, Goldstein JA. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 2003; 13: 461–472
   PubMedGoogle Scholar
• MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, Holt DW. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. American Journal of Transplantation 2004; 4: 914–919
   PubMed Web of Science ®Google Scholar
• Nebert DW, Menon AG. Pharmacogenomics, ethnicity, and susceptibility genes. Pharmacogenomics Journal 2001; 1: 19–22
   PubMedGoogle Scholar
• Quaranta S, Chevalier D, Bourgarel-Rey V, Allorge D, Solas C, Lo-Guidice JM, Sampol-Manos E, Vacher-Coponat H, Moal V, Broly F, et al. Identification by single-strand conformational polymorphism analysis of known and new mutations of the CYP3A5 gene in a French population. Toxicology Letters 2006; 164: 177–184
   PubMed Web of Science ®Google Scholar
• Roy JN, Lajoie J, Zijenah LS, Barama A, Poirier C, Ward BJ, Roger M. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metabolism and Disposition 2005; 33: 884–887
   PubMed Web of Science ®Google Scholar
• Saeki M, Saito Y, Nakamura T, Murayama N, Kim SR, Ozawa S, Komamura K, Ueno K, Kamakura S, Nakajima T, et al. Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Human Mutation 2003; 21: 653–659
   PubMedGoogle Scholar
• Schuetz JD, Beach DL, Guzelian PS. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 1994; 4: 11–20
   PubMedGoogle Scholar
• Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, Daly AK. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76: 1233–1235
   PubMed Web of Science ®Google Scholar
• Wojnowski L, Turner PC, Pedersen B, Hustert E, Brockmoller J, Mendy M, Whittle HC, Kirk G, Wild CP. Increased levels of aflatoxin–albumin adducts are associated with CYP3A5 polymorphisms in The Gambia, West Africa. Pharmacogenetics 2004; 14: 691–700
   PubMedGoogle Scholar
• Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Molecular Pharmacology 1990; 38: 207–213
   PubMed Web of Science ®Google Scholar
• Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5: 243–272
   PubMed Web of Science ®Google Scholar